A case report by Raven et al described a 36-year-old female (BMI 29.3 kg/m2) with a 27-year history of T1D and undetectable C-peptide, who used semaglutide (0.25 mg weekly increased to 0.5 mg weekly) “off-label.” Over six months, she experienced a 16-kg weight loss and a 36% reduction in insulin dose, with improved HbA1c and reduced glycemic variability, without an increase in hypoglycemia.3 This evidence concerns the gene INS and Hypoglycemia.